Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter

Human Gene Therapy

Volumn 15, Issue 4, 2004, Pages 339-350

  Zhang, Yun ^a   Schlachetzki, Felix ^a,b   Zhang, Yu Feng ^a   Boado, Ruben J ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; APOMORPHINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOLIPOSOME; MACROGOL; MALEIMIDE; MONOCLONAL ANTIBODY; OXIDOPAMINE; PLASMID DNA; TRANSFERRIN RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORPUS STRIATUM; ENCAPSULATION; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER; MALE; MOTOR DYSFUNCTION; NERVE CELL MEMBRANE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PARKINSONISM; PROMOTER REGION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIMIAN VIRUS 40;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CELL NUCLEUS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CORPUS STRIATUM; GENE THERAPY; GLIOMA; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PROMOTER REGIONS (GENETICS); RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFERRIN; RECOVERY OF FUNCTION; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; SIMIAE; SIMIAN VIRUS 40;

EID: 1842636306     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303404322959498     Document Type: Article

References (38)

1. ANDERTON, B.H., BREINBURG, D., DOWNES, M.J., GREEN, P.J., TOMLINSON, B.E., ULRICH, J., WOOD, J.N., and KAHN, J. (1998). Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature 298, 84-86.
2. BOADO, R.J., and PARDRIDGE, W.M. (1998). Ten nucleotide cis element in the 3′-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. Mol. Brain Res. 59, 109-113.
3. BOADO, R.J., LI, J.Y., NAGAYA, M., ZHANG, C., and PARDRIDGE, W.M. (1999). Selective expression of the large neutral amino acid transporter (LAT) at the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 96, 12079-12084.
4. BRENNER, M., KISSEBERTH, W.C., SU, Y., BESNARD, F., and MESSING, A. (1994). GFAP promoter directs astrocyte-specific expression in transgenic mice. J. Neurosci. 14, 1030-1037.
5. CONDORELLI, D.F., DELL'ALBANI, P., CONTICELLO, S.G., BARRESI, V., NICOLETTI, V.G., CARUSO, A., KAHN, M., VACANTI, M., ALBANESE, V., and DE VELLIS, J. (1997). A neural-specific hypomethylated domain in the 5′ flanking region of the glial fibrillary acidic protein gene. Dev. Neurosci. 19, 446-456.
6. DEBUS, E., WEBER, K., and OSBORN, M. (1983). Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation 25, 193-203.
7. FINKELSTEIN, D.I., STANIC, D., PARISH, D., TOMAS, D., DICKSON, K., and HORNE, M.K. (2000). Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97, 99-112.
8. GALOU, M., POURIN, S., ENSERGEUIX, D., RIDET, J.-L., TCHELINGERIAN, J.L., LOSSOUARN, L., PRIVAT, A., BABINET, C., and DUPOUEY, P. (1994). Normal and pathological expression of GFAP promoter elements in transgenic mice. Glia 12, 281-293.
9. GOMES, F.C.A., GARCIA-ABREU, J., GALOU, M., PAULIN, D., and NETO, V.M. (1999). Neurons induce GFAP gene promoter of cultured astrocytes from transgeneic mice. Glia 26, 97-108.
10. HORGER, B.A., NISHIMURA, M.C., ARMANINI, M.P., WANG, L.C., POULSEN, K.T., ROSENBLAD, C., KIRIK, D., MOFFAT, B., SIMMONS, L., JOHNSON, E., Jr., MILBRANDT, J., ROSENTHAL, A., BJORKLUND, A., VANDLEN, R.A., HYNES, M.A., and PHILLIPS, H.S. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18, 4929-4937.
11. HWANG, O., BAKER, H., GROSS, S., and JOH, T.H. (1998). Localization of GTP cyclohydrolase in monaminergic but not nitric oxide-producing cells. Synapse 28, 140-153.
12. JEFFERIES, W.A., BRANDON, M.R., HUNT, S.V., WILLIAMS, A.F., GATTERS, K.C., and MASON, D.Y. (1984). Transferrin receptor on endothelium of brain capillaries. Nature 312, 162-163.
13. KANEDA, N., SASAOKA, T., KOBAYASHI, K., KIUCHI, K., NAGATSU, I., KUROSAWA, Y., FUJITA, K., YOKOYAMA, M., NOMURA, T., KATSUKI, M., and NAGATSU, T. (1991). Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron 6, 583-594.
14. KANEKO, R., and SUEOKA, N. (1993). Tissue-specific versus cell type-specific expression of the glial fibrillary acidic protein. Proc. Natl. Acad. Sci. U.S.A. 90, 4698-4702.
15. LIU, J., SOLWAY, K., MESSING, R.O., and SHARP, F.R. (1998). Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J. Neurosci. 18, 7768-7778.
16. MANDEL, R.J., RENDAHL, K.G., SNYDER, R.O., and LEFF, S.E. (1999). Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adenoassociated viral vectors. Exp. Neurol. 159, 47-64.
17. MANDERS, E.M., VERBEEK, F.J., and ATEN, J.A. (1993). Measurements of co-localization of objects in dual-color confocal images. J. Microscopy 169, 375-382.
18. MANDIL, R., ASHKENAZI, E., BLASS, M., KRONFELD, I., KAZIMIRSKY, G., ROSENTHAL, G., UMANSKY, F., LORENZO, P.S., BLUMBERG, P.M., and BRODIE, C. (2001). Protein kinase Ca and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. 61, 4612-4619.
19. MIN, N., JOH, T.H., KIM, K.S., PENG, C., and SON, J.H. (1994). 5′ upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. Mol. Brain Res. 27, 281-289.
20. MOURADIAN, M.M., and CHASE, T.N. (1997). Gene therapy for Parkinson's disease: An approach to the prevention or palliation of levodopa-associated motor complications. Exp. Neurol. 144, 51-57.
21. NAGATSU, I., ICHINOSE, H., SAKAI, M., TITANI, K., SUZUKI, M., and NAGATSU, T. (1995). Immunocytochemical localization of GTP cyclohydrolase I in the brain, adrenal gland, and liver of mice. J. Neural Transm. 102, 175-188.
22. NAGATSU, I., ARAI, R., SAKAI, M., YAMAWAKI, Y., TAKEUCHI, T., KARASAWA, N., and NAGATSU, T. (1997). Immunohistochemical colocalization of GTP cyclohydrolase I in the nigrostriatal system with tyrosine hydroxylase. Neurosci. Lett. 224, 185-188.
23. PARDRIDGE, W. (2002). Drug and gene delivery to the brain: The vascular route. Neuron 36, 555-558.
24. PARDRIDGE, W.M., EISENBERG, J., and YANG, J. (1987). Human blood-brain barrier transferrin receptor. Metabolism 36, 892-895.
25. PARISH, C.L., FINKELSTEIN, D.I., TRIPANICHKUL, W., SATOSKAR, A.R., DRAGO, J., and HORNE, M.K. (2002). The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. J. Neurosci. 22, 8034-8041.
26. SEGOVIA, J., VERGARA, P., and BRENNER, M. (1998). Differentiation- dependent expression of transgenes in engineered astrocyte cell lines. Neurosci. Lett. 242, 172-176.
27. SHI, N., and PARDRIDGE, W.M. (2000). Non-invasive gene targeting to the brain. Proc. Natl. Acad. Sci. U.S.A. 97, 7567-7572.
28. SHI, N., ZHANG, Y., BOADO, R.J., ZHU, C., and PARDRIDGE, W.M. (2001a). Brain-specific expression of an exogenous gene following intravenous administration. Proc. Natl. Acad. Sci. U.S.A. 98, 12754-12759.
29. SHI, N., BOADO, R.J., and PARDRIDGE, W.M. (2001b). Receptor-mediated gene targeting to tissues in the rat in vivo. Pharm. Res. 18, 1091-1095.
30. SHIMOJI, M., HIRAYAMA, K., HYLAND, K., and KAPATOS, G. (1999). GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice. J. Neurochem. 72, 757-764.
31. ZHANG, Y., LEE, H.J., BOADO, R.J., and PARDRIDGE, W.M. (2002a). Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 4, 183-525.
32. ZHANG, Y., ZHU, C., and PARDRIDGE, W.M. (2002b). Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67-72.
33. ZHANG, Y., CALON, F., ZHU, C., BOADO, R.J., and PARDRIDGE, W.M. (2003a). Intravenous non-viral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism. Hum. Gene Ther. 14, 1-12.
34. ZHANG, Y., BOADO, R.J., and PARDRIDGE, W.M. (2003b). Marked enhancement in gene expression by targeting the human insulin receptor. J. Gene Med. 5, 157-163.
35. ZHANG, Y., SCHLACHETZKI, F., and PARDRIDGE, W.M. (2003c). Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7, 11-18.
36. ZHANG, Y., SCHLACHETZKI, F., LI, J.Y., BOADO, R.J., and PARDRIDGE, W.M. (2003d). Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9, 465-472.
37. ZHANG, Y.-.F, BOADO, R.I., and PARDRIDGE, W.M. (2003e). Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm. Res. 20, 1779-1785.
38. ZHUO, L., THES, M., ALVAREZ-MAYA, I., BRENNER, M., WILLECKE, K., and MESSING, A. (2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis 31, 85-94.